M
Michael R. Stratton
Researcher at Wellcome Trust Sanger Institute
Publications - 464
Citations - 162105
Michael R. Stratton is an academic researcher from Wellcome Trust Sanger Institute. The author has contributed to research in topics: Cancer & Mutation. The author has an hindex of 161, co-authored 443 publications receiving 142586 citations. Previous affiliations of Michael R. Stratton include University of Cambridge & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Testicular microlithiasis as a familial risk factor for testicular germ cell tumour.
J. Coffey,Robert Huddart,Faye Elliott,S.A. Sohaib,E. Parker,Darshna Dudakia,J L Pugh,Doug Easton,D.T. Bishop,Michael R. Stratton,E. A. Rapley +10 more
TL;DR: It is suggested that TM is an alternative manifestation of a TGCT susceptibility allele, which could be due to shared exposures, and likely that there exists a genetic susceptibility to TM that also predisposes to TGCT.
Journal ArticleDOI
A novel Gln358Glu mutation in ectodysplasin A associated with X-linked dominant incisor hypodontia.
Patrick S. Tarpey,Trevor J. Pemberton,David W. Stockton,David W. Stockton,Parimal Das,Vasiliki Ninis,Sarah Edkins,P. Andrew Futreal,Richard Wooster,Sushanth Kamath,Rabindra Nayak,Michael R. Stratton,Pragna Patel +12 more
TL;DR: This research presents a novel and scalable approach to genome-directed cell reprograming that aims to provide real-time information about the response of the immune system to foreign substance abuse.
Journal ArticleDOI
Mechanisms of APOBEC3 mutagenesis in human cancer cells
Mia Petljak,Alexandra Dananberg,Kevan Chu,Erik N. Bergstrom,Josefine Striepen,Patrick von Morgen,Yanyang Chen,H. Shah,Julian E. Sale,Ludmil B. Alexandrov,Michael R. Stratton,John Maciejowski +11 more
TL;DR: In this paper , the authors investigated the mechanisms of APOBEC3 mutagenesis by deleting implicated genes from human cancer cell lines that naturally generate APOEC3-associated mutational signatures over time.
Journal ArticleDOI
Screening for BRCA2 mutations in 81 Dutch breast–ovarian cancer families
T. Peelen,M. van Vliet,M. van Vliet,Anne Bosch,G. Bignell,Hans F. A. Vasen,J. G. M. Klijn,Hanne Meijers-Heijboer,Michael R. Stratton,G.J.B. van Ommen,Cees J. Cornelisse,Peter Devilee +11 more
TL;DR: Large genomic rearrangements within the BRCA2 gene do not represent a major mutation mechanism among Dutch breast cancer families.